The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10233 malaria professionals are enjoying the free benefits of MalariaWorld today

lumefantrine

Not Open Access | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

August 15, 2012 - 09:51 -- Patrick Sampao
Author(s): 
Pauline Byakika-Kibwika, Mohammed Lamorde, Concepta Merry, et al.
Reference: 
J. Antimicrob. Chemother. (2012) 67 (9): 2213-2221

MalariaWorldWe investigated drug–drug interactions between artemether/lumefantrine and efavirenz or nevirapine.

Person: 
Country: 
Medical Treatment: 

NOT Open Access | The Spiroindolone Drug Candidate NITD609 Potently Inhibits Gametocytogenesis and Blocks Plasmodium falciparum Transmission to Anopheles Mosquito Vector

June 20, 2012 - 08:50 -- Kabogo Ndegwa
Author(s): 
J. C. van Pelt-Koops, H. E. Pett, W. Graumans, M. van der Vegte-Bolmer, G. J. van Gemert, M. Rottmann, B. K. S. Yeung, T. T. Diagana, and R. W. Sauerwein
Reference: 
Antimicrob. Agents Chemother. July 2012 vol. 56 no. 7 3544-3548

MalariaWorldThe global malaria agenda has undergone a reorientation from control of clinical cases to entirely eradicating malaria.

In Vitro Sensitivity of Plasmodium falciparum from China-Myanmar Border Area to Major ACT Drugs and Polymorphisms in Potential Target Genes

June 14, 2012 - 07:59 -- Kabogo Ndegwa
Author(s): 
Zenglei Wang, Daniel Parker, Zhaoqing Yang, et al.
Reference: 
PLoS ONE 7(5): e30927

MalariaWorldDrug resistance has always been one of the most important impediments to global malaria control.

Country: 
Medical Condition: 

The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against plasmodium falciparum

May 29, 2012 - 12:23 -- Kabogo Ndegwa
Author(s): 
Chotivanich K, Mungthin M, Ruengweerayuth R, Udomsangpetch R, Dondorp AM, Singhasivanon P, Pukrittayakamee S, White NJ
Reference: 
Malaria Journal 2012, 11:177 (28 May 2012)

MalariaWorldLipidaemia reduces the anti-malarial activity of lipophilic anti-malarial drugs.

Medical Condition: 
Medical Treatment: 

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults

April 10, 2012 - 14:59 -- Patrick Sampao
Author(s): 
Pauline Byakika-Kibwika, Mohammed Lamorde, Concepta Merry, et al.
Reference: 
J. Antimicrob. Chemother. (2012) 67 (5): 1217-1223.

MalariaWorldWe investigated the pharmacokinetics of artemether, dihydroartemisinin and lumefantrine after administration of a single dose of 80/480 mg of artemether/lumefantrine to HIV-infected adults, taken with and without lopinavir/ritonavir.

Country: 
Medical Condition: 
Medical Treatment: 

Short Report: Successful Oral Therapy for Severe Falciparum Malaria: The World Health Organization Criteria Revisited

March 9, 2012 - 13:34 -- Patrick Sampao
Author(s): 
Eran Kopel, Enbal Marhoom, Yechezkel Sidi and Eli Schwartz
Reference: 
Am J Trop Med Hyg 2012 86:409-411

MalariaWorldWe report a successful treatment of severe falciparum malaria in a non-immune adult patient with 30% parasitemia treated with the 6-dose oral regimen of artemether plus lumefantrine combination therapy alone.

Medical Condition: 
Medical Treatment: 

Open Access | Genome Wide Adaptations of Plasmodium falciparum in Response to Lumefantrine Selective Drug Pressure

March 6, 2012 - 07:56 -- Kabogo Ndegwa
Author(s): 
Leah Mwai, Abdi Diriye, Victor Masseno, Steven Muriithi, Theresa Feltwell, Jennifer Musyoki, Jacob Lemieux, Avi Feller, Gunnar R. Mair, Kevin Marsh, Chris Newbold, Alexis Nzila, Céline K. Carret
Reference: 
PLoS ONE 7(2): e31623

MalariaWorldThe combination therapy of the Artemisinin-derivative Artemether (ART) with Lumefantrine (LM) (Coartem®) is an important malaria treatment regimen in many endemic countries.

Medical Condition: 

Population Pharmacokinetics of Artemether, Lumefantrine, and Their Respective Metabolites in Papua New Guinean Children with Uncomplicated Malaria

October 17, 2011 - 10:24 -- Kabogo Ndegwa
Author(s): 
Sam Salman, Madhu Page-Sharp, Susan Griffin, Kaye Kose, Peter M. Siba, Kenneth F. Ilett, Ivo Mueller, and Timothy M. E. Davis
Reference: 
Antimicrobial Agents and Chemotherapy, November 2011,p. 5306-5313, Vol. 55, No. 11

MalariaWorldThere are sparse published data relating to the pharmacokinetic properties of artemether, lumefantrine, and their active metabolites in children, especially desbutyl-lumefantrine.

Medical Condition: 
Medical Treatment: 

Open Access | Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats

October 11, 2011 - 07:20 -- Kabogo Ndegwa
Author(s): 
Wahajuddin, Singh SP, Raju KS, Nafis A, Puri SK, Jain GK
Reference: 
Malaria Journal 2011, 10:293 (10 October 2011)

MalariaWorldThe pharmacokinetic parameters of lumefantrine and its metabolite desbutyl-lumefantrine were successfully determined in rats for the first time.

Medical Condition: 
Medical Treatment: 

Open Access | Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine

March 2, 2011 - 09:11 -- Kabogo Ndegwa
Author(s): 
Verbeken M, Suleman S, Baert B, Vangheluwe E, Van Dorpe S, Burvenich C, Duchateau L, Jansen FH, De Spiegeleer B
Reference: 
Malaria Journal 2011, 10:51 (28 February 2011)

From unstressed, stressed and accelerated stability samples of lumefantrine API and FPPs, nine compounds were detected and characterized to be lumefantrine related impurities.

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - lumefantrine